Eveliqure Announces Dosing of First Participants in a Phase 2b study of the ShigETEC Vaccine in Shigellosis
VIENNA, AUSTRIA, July 23, 2025 /EINPresswire.com/ -- • Phase 2b study to assess immunogenicity and efficacy of the oral ShigETEC vaccine against Shigellosis • Study entails vaccination of participants followed by a Controlled Human Infectious Model ( …